Breaks Categories: Stock Spotlights

FridaySep 15, 2023 12:11 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma (“GBM”) and neuro-oncology, recently presented updated safety results from its potentially pivotal clinical study on GBM treatment through its lead drug candidate, Berubicin. “Most notably, this novel anthracycline demonstrated its capability to be a safe and innovative potential treatment option for GBM, having shown aspects integral to effective therapy for the disease… So far, 151 patients have been enrolled in the clinical study, with 105 set on Berubicin while the remaining 46 will be on Lomustine. This marks…

Continue Reading

WednesdaySep 06, 2023 3:26 pm

BioMedNewsBreaks — Why RVL Pharmaceuticals plc (NASDAQ: RVLP) Is ‘One to Watch’

RVL Pharmaceuticals (NASDAQ: RVLP) is a specialty pharmaceutical company focusing on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution), 0.1%, available by prescription for the treatment of acquired blepharoptosis (low-lying eyelid(s)) in adults. “UPNEEQ(R) (‘RVL-1201’) is the first non-surgical treatment option approved by the U.S. Food and Drug Administration (‘FDA’) for acquired blepharoptosis. The company received FDA approval in July 2020 and launched UPNEEQ(R) in September 2020 to a limited number of eye care professionals, with commercial operations expanded in 2021 among ophthalmology, optometry and oculoplastic specialties,” a recent article reads. “In February 2022, UPNEEQ(R) was launched into the medical…

Continue Reading

FridaySep 01, 2023 2:50 pm

BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for Eli Lilly and Company’s (NYSE: LLY) acquisition of DICE Therapeutics Inc. (NASDAQ: DICE), a biopharmaceutical company that develops oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in…

Continue Reading

FridaySep 01, 2023 12:17 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (‘NSCLC’). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed…

Continue Reading

FridayAug 25, 2023 2:14 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very promising drug. Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a…

Continue Reading

MondayAug 07, 2023 1:05 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities

CNS Pharmaceuticals (NASDAQ: CNSP), a Texas-based cancer drug innovator, is focused on advancing its potentially pivotal clinical trial to track the effectiveness of drug candidate Berubicin in treating glioblastoma (“GBM”) brain cancers. Berubicin has already produced one patient with over 15 years of GBM survival. “Berubicin distinguishes itself by being virtually unique in its status as a cancer-fighting anthracycline that crosses the blood-brain barrier to attack central nervous system tumors directly. Berubicin also distinguished itself by presenting statistically significant improvement in nearly half of the two dozen patients evaluated in a phase I trial in 2006, including one patient whose…

Continue Reading

FridayJul 28, 2023 12:41 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leveraging Unique NanoAb Pipeline to Target Large, Growing Markets

BiondVax (NASDAQ: BVXV) is an innovative biotechnology company focused on developing, manufacturing and commercializing potential blockbuster immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company is developing a pipeline of unique nanosized antibody (“NanoAb”) therapies addressing diseases underserved by current treatments with large, growing markets, including dermatological conditions such as psoriasis. “BiondVax is initially targeting IL-17 [the human immune system cytokine, which is implicated in several diseases] for the treatment of psoriasis, where the market for therapeutics is expected to reach $44 billion by 2031,” reads a recent article. “The company’s plan for the IL-17 nanobody…

Continue Reading

MondayJul 24, 2023 3:17 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.’s (NASDAQ: BVXV) CDMO Services Designed to Meet Needs of Pharmaceutical, Biotechnology Companies of All Sizes

BiondVax (NASDAQ: BVXV) is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. The company recently showcased its boutique end-to-end contract development and manufacturing organization (“CDMO”) services and expertise at a leading conference for International Life Science and HealthTech industries, the Biomed Conference, in Tel Aviv. “These CDMO services will allow BiondVax to partner with pharmaceutical companies to provide contract-based drug development and manufacturing services, leveraging its Good Manufacturing Practices (‘GMP’) biologics manufacturing facility in Jerusalem… The company’s CDMO services are designed to meet the needs of pharmaceutical…

Continue Reading

MondayJul 17, 2023 2:15 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Positioned to Expand Its Clinical Pipeline

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently announced that its research collaborators presented positive preclinical data for the reexpression of the NPRL2 gene. “The collaborators conducted the studies using the ONCOPREX(R) Nanoparticle Delivery System to deliver the NPRL2 gene to KRAS/STK11 mutant, anti-PD1 resistant, human NSCLC metastases in humanized mouse models, presenting the data at the 2023 American Association of Cancer Research (‘AACR’) annual meeting, held in April,” reads a recent article. “According to Genprex President, Chairman and CEO Rodney Varner, the use of ONCOPREX(R) to deliver…

Continue Reading

MondayJul 03, 2023 11:31 am

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Well Positioned to Move next NanoAb Candidates into Clinical Application

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, recently signed an exclusive worldwide license agreement to develop and commercialize VHH antibodies (“NanoAbs”) that target Interleukin-17 (“IL-17”). “The license agreement is part of a broad-based collaboration with the Max Planck Society and the University Medical Center Göttingen (‘UMG’). The NanoAbs will be targeted toward the treatment of several relevant indications, including, but not limited to, psoriasis and psoriatic arthritis. BiondVax’s collaboration with the Max Planck Institute for Multidisciplinary Sciences and UMG, both based in Germany,…

Continue Reading